Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: A 5-year survival analysis

被引:21
|
作者
Donizy, Piotr [1 ]
Kaczorowski, Maciej [1 ]
Leskiewicz, Marek [2 ]
Zietek, Marcin [3 ]
Pieniazek, Malgorzata [4 ,5 ]
Kozyra, Cyprian [2 ]
Halon, Agnieszka [1 ]
Matkowski, Rafal [3 ,4 ,5 ]
机构
[1] Wroclaw Med Univ, Dept Pathomorphol & Oncol Cytol, PL-50556 Wroclaw, Poland
[2] Wroclaw Univ Econ, Dept Stat, PL-53345 Wroclaw, Poland
[3] Lower Silesian Oncol Ctr, PL-53413 Wroclaw, Poland
[4] Wroclaw Med Univ, Dept Oncol, PL-53413 Wroclaw, Poland
[5] Wroclaw Med Univ, Div Surg Oncol, PL-53413 Wroclaw, Poland
关键词
mitotic rate; ulceration; melanoma; prognosis; AMERICAN JOINT COMMITTEE; LYMPH-NODE POSITIVITY; CANCER STAGING SYSTEM; INVASION; PREDICTOR;
D O I
10.3892/or.2014.3531
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of ulceration has been considered as one of the most important primary tumor characteristics of cutaneous malignant melanoma (CMM) for predicting patient outcome. Yet recently, scientific attention has been drawn towards another microscopic feature of primary tumors, the mitotic rate (MR). The present study aimed to examine the relationship between the presence of ulceration and the mitotic rate and clinicopathological characteristics and melanoma patient survival, and to discuss the results in the context of AJCC melanoma staging recommendations. Tissue samples were obtained from 104 patients treated for CMM. In classical H&E staining, the mitotic rate and the presence of ulceration were evaluated. Non-mitogenic tumors were defined as having 0 mitoses/mm(2), low mitogenic potential, 1-2 mitoses/mm(2) and highly mitogenic tumors, >= 3 mitoses/mm(2). In the entire group of 104 patients, a high mitotic rate (hMR) and ulceration were highly negative prognostic factors, and indicated considerably shorter overall survival, cancer-specific overall survival and disease-free survival. Notably, hMR appeared to have a statistically significant negative impact on survival in early melanomas in both the pT1 (P=0.001) and pT2 subgroups (P=0.006). Kaplan-Meier analysis of the remaining subsets (pT3 and pT4) did not reveal any important differences in the 5-year survival with regard to MR values. The presence of ulceration also had a prognostic significance for early melanomas, but only for pT1 tumors (P=0.05). Multivariate analysis confirmed that hMR was strongly associated with an unfavorable prognosis. Ulceration had no prognostic significance in the Cox proportional hazards model. Considering the biology of melanoma, hMR seems to be a more reliable parameter than the presence of ulceration. The value of MR categorizes melanomas into tumors with low or high proliferative potential, thus giving direct information concerning their capacity to infiltrate deeper layers of the dermis and, potentially, to generate regional lymph node and distant metastases.
引用
收藏
页码:2735 / 2743
页数:9
相关论文
共 48 条
  • [41] Comparison of the more than 5-year clinical outcomes of cervical disc arthroplasty versus anterior cervical discectomy and fusion: A protocol for a systematic review and meta-analysis of prospective randomized controlled trials (vol 95, e5733, 2016)
    Chen, Chun-Hui
    Lin, Zhong-Ke
    Wang, Xiang-Yang
    Huang, Qi-Shan
    Chi, Yong-Long
    Wu, Ai-Min
    MEDICINE, 2017, 96 (08)
  • [42] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
    Andre, V.
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E.
    Huang, C. -s.
    Senkus, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R.
    Munoz, M.
    Antonio, B. S.
    Shahir, A.
    Martin, M.
    Johnston, S.
    BREAST, 2025, 80
  • [43] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Reinisch, Mattea
    Harbeck, Nadia
    Rastogi, Priya
    O'shaughnessy, Joyce
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Hamilton, Erika
    Goetz, Matthew P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Trakin, Alexey
    Neven, Patrick
    Huober, Jens
    Ran, Wei
    Andre, Valerie
    Munoz-Fernandez, Maria
    Antonio, Belen San
    Shahir, Ashwin
    Martin, Miguel
    Johnston, Stephen
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 227 - 228
  • [44] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E. P.
    Huang, C.
    Senkus-Konefka, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R. J.
    Andre, V.
    Munoz, M.
    Antonio, B. San
    Shahir, A.
    Jimenez, M. Martin
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
  • [46] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
    Rastogi, Priya
    O'Shaughnessy, Joyce
    Martin, Miguel
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Goetz, Matthew P.
    Hamilton, Erika P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Tryakin, Alexey
    Cicin, Irfan
    Testa, Laura
    Neven, Patrick
    Huober, Jens
    Shao, Zhimin
    Wei, Ran
    Andre, Valerie
    Munoz, Maria
    San Antonio, Belen
    Shahir, Ashwin
    Harbeck, Nadia
    Johnston, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09) : 987 - 993
  • [47] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 42, 10.1200/JCO.23.01994, 2024)
    Rastogi, Priya
    O'Shaughnessy, Joyce
    Martin, Miguel
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Goetz, Matthew P.
    Hamilton, Erika P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Tryakin, Alexey
    Cicin, Irfan
    Testa, Laura
    Neven, Patrick
    Huober, Jens
    Shao, Zhimin
    Wei, Ran
    Andre, Valerie
    Munoz, Maria
    San Antonio, Belen
    Shahir, Ashwin
    Harbeck, Nadia
    Johnston, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2111 - 2111